Lyka Labs logo

Lyka Labs

LYKALABS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹301 Cr
Volatility
High Risk
P/E Ratio
-32.3
EBITDA
₹0.00 Cr
Return on Equity
-11.49%
Debt to Equity
0.53
Book Value
₹25.68
52W High
₹101.9
52W Low
₹44.1

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 32.4 days to 22.7 days

Weaknesses

5
  • Stock is trading at 3.20 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 8.29% over past five years.
  • Company has a low return on equity of -2.04% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
-6.25% lower than 3Y
Net Income Growth
-232% lower than 3Y
Cash Flow Change
176% lower than 3Y
ROE
-250% lower than 3Y
ROCE
-168% higher than 3Y
EBITDA Margin (Avg.)
-99.93% level than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
22.88
27.99
32.56
27.77
30.11
41.16
33.8
33.43
33.03
36.66
30.73
28.03
42.31
Expenses
20.24
23.82
25.69
25.75
26.4
36.21
28.61
29.35
29.35
39.2
29.08
34.48
37.76
Operating Profit
2.64
4.17
6.87
2.02
3.71
4.95
5.19
4.08
3.68
-2.54
1.65
-6.45
4.55
OPM %
11.54%
14.9%
21.1%
7.27%
12.32%
12.03%
15.36%
12.2%
11.14%
-6.93%
5.37%
-23.01%
10.75%
Other Income
0.38
-0.18
0.54
0.32
0.56
0.03
0.83
0.82
0.63
1.09
1.16
0.61
0.42
Interest
1.35
1.19
1.28
1.07
0.65
0.54
0.61
0.47
0.85
0.79
0.82
0.7
1.01
Depreciation
3.47
3.59
2.84
2.9
1.76
1.76
1.83
1.42
2.11
2.15
2.15
2.04
2.01
PBT
-1.8
-0.79
3.29
-1.63
1.86
2.68
3.58
3.01
1.35
-4.39
-0.16
-8.58
1.95
Tax %
7.22%
-22.78%
38.6%
28.22%
30.65%
28.36%
24.3%
32.89%
26.67%
-26.65%
-6.25%
-6.06%
-5.13%
Net Profit
-1.85
-0.49
1.78
-2.09
1.29
1.91
2.7
2.03
0.99
-3.22
-0.15
-8.07
2.05
EPS in Rs
-0.56
-0.15
0.54
-0.63
0.4
0.59
0.76
0.5
0.26
-0.94
0
-2.13
0.57
Figures in ₹ Crores

Profit & Loss

Particulars Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
166
130
110
60
71
61
86
194
93
111
138
128
138
Expenses
139
110
87
63
73
65
67
93
76
95
121
132
141
Operating Profit
28
20
23
-4
-2
-4
20
101
17
16
18
-3
-3
OPM %
17%
16%
21%
-6%
-2.7%
-6%
23%
52%
18%
14%
13%
-2.7%
-2%
Other Income
4
8
-2
4
1
-30
0
-4
-4
1
2
4
3
Interest
24
15
19
10
7
20
26
20
12
5
2
3
3
Depreciation
11
9
10
11
7
8
8
17
14
13
7
8
8
PBT
-3
4
-8
-20
-15
-62
-14
59
-13
-1
11
-12
-11
Tax %
31%
-5%
-19%
-5%
-59%
1%
-29%
35%
0%
182%
29%
-11%
—
Net Profit
-5
4
-7
-19
-6
-63
-10
38
-13
-3
8
-10
-9
EPS in Rs
-2.29
1.67
-2.51
-6.14
-1.97
-21.1
-4.03
13.59
-4.3
-0.75
2.24
-2.81
-2.5
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
22
22
22
28
28
29
29
29
31
33
36
36
Reserves
20
22
16
21
15
-43
-54
-15
15
35
69
57
Borrowings
137
121
126
113
96
141
163
130
75
59
39
49
Other Liabilities
100
77
88
67
76
73
52
42
31
30
32
33
Total Liabilities
279
242
252
229
216
200
190
186
152
157
176
175
Fixed Assets
122
104
133
116
108
105
98
94
68
58
85
87
CWIP
27
30
24
28
31
28
26
18
16
23
1
2
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
130
107
94
85
77
68
66
74
67
76
90
86
Total Assets
279
242
252
229
216
200
190
186
152
157
176
175
Figures in ₹ Crores

Cash Flow

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
27
12
31
11
27
5
9
79
9
2
2
5
Investing
37
17
-13
-3
-4
0
0
-6
7
-9
-12
-9
Financing
-60
-30
-19
-10
-23
3
-12
-63
-22
2
5
4
Net Cash Flow
4
-1
0
-3
-1
9
-3
10
-5
-6
-5
0
Free Cash Flow
55
28
18
7
23
4
8
72
15
-7
-10
-6
CFO/OP
97
60
143
-318
-1,462
-131
49
79
52
21
28
-159
Figures in ₹ Crores

Ratios

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
124
121
97
125
75
48
37
35
79
89
114
100
Inventory Days
77
56
90
139
65
69
41
56
68
78
82
99
Days Payable
220
218
266
301
216
192
141
96
91
98
98
122
Cash Conversion Cycle
-18
-41
-79
-37
-75
-76
-63
-5
55
68
97
76
Working Capital Days
-220
-242
-357
-735
-265
-242
-118
-121
0
23
51
23
ROCE %
10%
7%
9%
-8%
-5%
-6%
10%
61%
5%
4%
10%
-6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Lyka Labs insights

65 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

FIIs0.17%Promot.58.45%DIIs0.66%Others9.54%Public31.18%As ofJun 2026

Documents

Frequently Asked Questions about Lyka Labs

What does Lyka Labs Ltd do?
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
Where is Lyka Labs Ltd (LYKALABS) listed?
Lyka Labs Ltd trades as LYKALABS on the NSE and under code 500259 on the BSE.
Which sector does Lyka Labs Ltd belong to?
Lyka Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Lyka Labs Ltd?
Lyka Labs Ltd has a market capitalisation of ₹300.51 Cr, which places it in the Small Cap band.
What is the PE ratio of Lyka Labs Ltd?
Lyka Labs Ltd trades at a PE ratio of -32.30, against a book value of ₹25.68 per share.
What is the 52-week high and low of Lyka Labs Ltd?
Over the last 52 weeks Lyka Labs Ltd has traded between ₹44.1 and ₹101.9.
What is the Return on Equity (ROE) of Lyka Labs Ltd?
Lyka Labs Ltd reported a return on equity of -11.49%. Its debt-to-equity ratio is 0.53.

Company Information

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Website lykalabs.com
CEO Mr. Kunal Narendra Gandhi
Employees 499
Listed 1995-02-08
Face Value ₹ 10
Issued Size 3,56,90,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LYKALABS.md for Lyka Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List